title: [Long-term outcome in patients with symptomatic low-grade oligodendrogliomatous tumors treated by cytotoxic agents].
abstract: BACKGROUND
  Whether aggressive treatment or no treatment is the optimal management for low-grade gliomas is controversial. However, symptomatic low-grade gliomas require prompt therapeutic intervention because of neurological impairment, uncontrolled seizures, and deterioration of life quality.
  
  
  METHODS
  We report the long-term follow-up, 71 months, of seven patients treated by procarbazine, lomustine and vincristine (PCV) therapy for a symptomatic low-grade oligodendrogliomatous tumor. The mean age at diagnosis was 47 years, the mean time from first symptoms to initiation of PCV therapy was 62 months (range 15-147).
  
  
  RESULTS
  All patients initially responded favorably, with improvement of the neurological symptoms and radiological response. Chemotherapy was clinically well tolerated, the main side effect being low hematological toxicity. During the follow-up, no progression was observed in two patients. For the five remaining patients, the time to progression after the PCV induction was 56+/-12 months (range 38 to 73). Four of these patients showed favorable response to a second line of treatment.
  
  
  CONCLUSIONS
  PCV therapy is an interesting therapeutic option for progressively symptomatic low-grade gliomas, even in cases with large tumoral volume. This treatment, of moderate toxicity, improves the quality of life and can result in long-term tumor stabilization.
authors.affiliation: Service de Neurologie B, Hôpital Neurologique, Lyon.
authors.forename: H
authors.initials: H
authors.lastname: Catenoix
authors.forename: J
authors.initials: J
authors.lastname: Honnorat
authors.forename: S
authors.initials: S
authors.lastname: Cartalat-Carel
authors.forename: F
authors.initials: F
authors.lastname: Chapuis
authors.forename: N
authors.initials: N
authors.lastname: Nighoghossian
authors.forename: P
authors.initials: P
authors.lastname: Trouillas
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008130:Lomustine / Q000008:administration & dosage; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009837:Oligodendroglioma / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D011344:Procarbazine / Q000008:administration & dosage; D011859:Radiography; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D011344:Procarbazine; D014750:Vincristine; D008130:Lomustine